(Reuters Health)—A once-daily 15 mg dose of upadacitinib for rheumatoid arthritis (RA) has similar rates of malignancies, serious infections, major adverse cardiovascular events, and venous thromboembolic events as other Janus kinase inhibitors (jakinibs), results from phase 3 clinical trials suggest. Researchers examined data on treatment emergent adverse events among patients taking upadacitinib in five randomized…
1 Step Closer: Study Examines Factors That Lead to RA in Hope of Developing Prevention Strategies
Research has found blood tests detect elevations of autoantibody isotypes in patients years before they are diagnosed with rheumatoid arthritis (RA). According to Kevin Deane, MD, PhD, identifying patients during this pre-RA period may be key to preventing or delaying the onset of RA.
Janus Kinase vs. TNF Inhibitors: The Context for Venous Thromboembolism Risk with RA Treatments
An observational study found treatment with tofacitinib resulted in only a slightly higher rate of venous thromboembolism than tumor necrosis factor inhibitors in patients with rheumatoid arthritis.
RA Patients Taking Either 15 mg or 30 mg Dose of Upadacitinib Experience Improvement
The SELECT-EARLY MTX-controlled trial examined the safety and efficacy of upadacitinib, a potent, reversible jakinib, as monotherapy in patients with moderately to highly active RA and poor prognostic features who are either naive for or have limited exposure to methotrexate.
For RA Patients, Functional Disability May Precede Diagnosis
In a study, researchers found rheumatoid arthritis patients experience a persistent burden of functional disability regardless of disease duration, age or gender.
Biologics May Prevent Cardiovascular Events in RA Patients
RA patients experience a higher rate of cardiovascular disease (CVD) events than controls. In a new study, Karpouzas et al. determined that current biologic disease-modifying anti-rheumatic drug use is associated with reduced long-term CVD risk, protective calcification of noncalcified lesions and a lower likelihood of new plaque formation in patients with early atherosclerosis.
ABX464 in Phase 2a Trials for RA
Research is examining the safety and tolerability of two different doses of ABX464 in patients with moderate to severe active RA…
Seronegative RA May Be on the Rise
A study comparing trends in the incidence of RA from 2005 to 2014 with previous decades showed a shift in RA subset, suggesting the need for timely recognition of rheumatoid factor-negative RA…
Clinical Criteria for RA & Early Non-Response to Certolizumab as Predictors of Patient Outcomes
A recent study compared three clinical criteria for rheumatoid arthritis (RA) in patients using certolizumab, assessing the predictability of treatment non-response. Researchers found Clinical Disease Activity Index measurement at three months may predict patient outcomes at 12 months…
Local Depletion of Resident Memory T Cells May Reduce Site-Specific Joint Flares
A study found resident memory T cells may mediate inflammatory arthritis and trigger flares in specific joints, suggesting local depletion of these cells could be a therapeutic strategy…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 30
- Next Page »